Use of mesenchymal stem cells or their culture supernatant
Culturing MSCs with imidazole dipeptide in a serum-free medium produces a culture supernatant and cells that enhance disease suppression and inhibit osteogenic differentiation, addressing the limitations of conventional MSC culture supernatants.
JP7873894B2Inactive Publication Date: 2026-06-15CELL EXOSOME THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- CELL EXOSOME THERAPEUTICS INC
- Filing Date
- 2025-02-13
- Publication Date
- 2026-06-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
⚠Technical Problem
The composition of conventional mesenchymal stem cell (MSC) culture supernatants requires improvement for effective disease suppression or improvement, and existing methods do not adequately inhibit osteogenic differentiation.
⚗Method used
Culturing MSCs in a medium containing imidazole dipeptide, either with or without serum, to produce a culture supernatant or cells that suppress or improve diseases, inhibit osteogenic differentiation, and promote the expression of specific cytokines and exosome secretion.
🎯Benefits of technology
The method yields a culture supernatant and MSCs that effectively suppress or improve diseases by enhancing cytokine concentrations and inhibit osteogenic differentiation, with improved safety profiles and enhanced cytokine expression.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007873894000005 
Figure 0007873894000006 
Figure 0007873894000007
Abstract
To provide a culture supernatant of mesenchymal stem cells or mesenchymal stem cells, containing components secreted from cells such as cytokines, useful for suppressing or improving disease; a pharmaceutical composition comprising mesenchymal stem cells; and a method for producing a pharmaceutical composition.SOLUTION: A culture supernatant of mesenchymal stem cells contains at least 500 pg / mL of G-CSF and at least 2700 pg / mL of IL-6. The culture supernatant preferably contains an imidazole dipeptide, and preferably further contains at least 670 pg / mL of TGF-β1, at least 3.5 pg / mL of IL-7, or at least 6500 pg / mL of IL-8.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art